ASXL1 and acute myeloid leukemia: Following studies provided further evidence regarding the incidental and non-malignant significance of the persistence of DNMT3A, TET2 and ASXL1 mutations detectable by NGS after initial induction chemotherapy for acute myeloid leukemia (AML) [20,21,22].